{
    "nctId": "NCT00733408",
    "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer",
    "phase": "Phase II",
    "recruitment": "Completed",
    "therapies": [
        {
            "id": 1496,
            "therapyName": "Bevacizumab + Erlotinib + Nab-paclitaxel",
            "synonyms": null
        }
    ],
    "ageGroups": [
        "adult"
    ],
    "gender": "female",
    "variantRequirements": "yes",
    "sponsors": "University of Washington",
    "updateDate": "12/05/2018",
    "indications": [
        {
            "id": 1612,
            "name": "breast cancer",
            "source": "DOID"
        }
    ],
    "variantRequirementDetails": [
        {
            "molecularProfile": {
                "id": 530,
                "profileName": "ERBB2 wild-type"
            },
            "requirementType": "required"
        },
        {
            "molecularProfile": {
                "id": 1189,
                "profileName": "PGR negative"
            },
            "requirementType": "required"
        },
        {
            "molecularProfile": {
                "id": 1190,
                "profileName": "ESR1 negative"
            },
            "requirementType": "required"
        }
    ]
}